Comparison of the virulence potential of Acinetobacter strains from clinical and environmental sources.
Several Acinetobacter strains have utility for biotechnology applications, yet some are opportunistic pathogens. We compared strains of seven Acinetobacter species (baumannii, Ab; calcoaceticus, Ac; guillouiae, Ag; haemolyticus, Ah; lwoffii, Al; junii, Aj; and venetianus, Av-RAG-1) for their potential virulence attributes, including proliferation in mammalian cell conditions, haemolytic/cytolytic activity, ability to elicit inflammatory signals, and antibiotic susceptibility. Only Ah grew at 10(2) and 10(4) bacteria/well in mammalian cell culture medium at 37°C. However, co-culture with colonic epithelial cells (HT29) improved growth of all bacterial strains, except Av-RAG-1. Cytotoxicity of Ab and Ah toward HT29 was at least double that of other test bacteria. These effects included bacterial adherence, loss of metabolism, substrate detachment, and cytolysis. Only Ab and Ah exhibited resistance to killing by macrophage-like J774A.1 cells. Haemolytic activity of Ah and Av-RAG-1 was strong, but undetectable for other strains. When killed with an antibiotic, Ab, Ah, Aj and Av-RAG-1 induced 3 to 9-fold elevated HT29 interleukin (IL)-8 levels. However, none of the strains altered levels of J774A.1 pro-inflammatory cytokines (IL-1β, IL-6 and tumor necrosis factor-α). Antibiotic susceptibility profiling showed that Ab, Ag and Aj were viable at low concentrations of some antibiotics. All strains were positive for virulence factor genes ompA and epsA, and negative for mutations in gyrA and parC genes that convey fluoroquinolone resistance. The data demonstrate that Av-RAG-1, Ag and Al lack some potentially harmful characteristics compared to other Acinetobacter strains tested, but the biotechnology candidate Av-RAG-1 should be scrutinized further prior to widespread use.
Biotechnology Laboratory, Environmental Health Sciences and Research Bureau, Environmental Health Centre, Health Canada, Ottawa, Canada. azam.tayabali@hc-sc.gc.ca
Azam F
AF
Tayabali
Kathy C
KC
Nguyen
Philip S
PS
Shwed
Jennifer
J
Crosthwait
Gordon
G
Coleman
Verner L
VL
Seligy
D000150:Acinetobacter / Q000187:drug effects / Q000235:genetics / Q000472:pathogenicity* / Q000502:physiology*; D000151:Acinetobacter Infections / Q000188:drug therapy / Q000382:microbiology*; D000595:Amino Acid Sequence; D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D002460:Cell Line; D002470:Cell Survival; D024881:Drug Resistance, Bacterial; D004912:Erythrocytes / Q000382:microbiology; D005798:Genes, Bacterial; D006461:Hemolysis; D054884:Host-Pathogen Interactions; D006801:Humans; D008264:Macrophages / Q000382:microbiology; D008969:Molecular Sequence Data; D010587:Phagocytosis; D016415:Sequence Alignment; D012756:Sheep
D000900:Anti-Bacterial Agents